CUI Annual Report 2020

CU INNOVATIONS 2020 ANNUAL REPORT FACES OF INNOVATION UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

A few words from our Executive Director Welcome to the 2020 CU Innovations Annual Report. This report highlights the ground-breaking innovations being developed on the Anschutz Medical Campus. This year’s report celebrates the faculty - the heroes who work tirelessly to deliver state of the art clinical care, to educate the medical leaders of tomorrow, and to develop the next generation of technologies that will transform healthcare. 2020 was marked by the COVID-19 pandemic, bringing with it, shortages in testing, therapeutics, and lifesaving equipment. Campus faculty and staff rose to the challenge by developing novel approaches for procuring personal protective equipment (PPE), standing up in-house COVID-19 testing capabilities, developing novel diagnostic, therapeutics and preventative treatments, and partnering with industry to develop solutions that can remotely monitor patients at home. The CU Anschutz response to the COVID-19 pandemic is a testament to the resilience, passion and commitment of our faculty and staff. Collectively, we have sought to embrace a culture that values integrity, collaboration and empowerment. In these unprecedented times, such as the last year, it has been inspiring to see our colleagues displaying these values daily and overcoming adversity without losing momentum. Over the past year, faculty and staff submitted nearly 200 new ideas for commercialization, 300+ companies sought to collaborate with CU Anschutz faculty on research, clinical trials, and product development, and our start-ups had a record-breaking year raising over $150M in follow-on funding. The NIH recognized the advancements of the campus by naming CU Anschutz as a top 5 innovation hub in the country and awarding a $4M grant to scale the CU Innovations SPARK program. We are currently working with our partners at CCTSI, the Cancer Center, Bioengineering, and the School of Pharmacy to make more educational, grant funding and mentorship opportunities available to faculty campus-wide, and to disseminate best practices. We are fortunate to work with world renowned clinicians and researchers, and this year, we celebrate those leaders. We thank and honor them for their contributions as we work together to build a lasting legacy of impact for patients worldwide. Sincerely, Kimberly Muller, Esq. Executive Director, CU Innovations 1 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

CONTENTS 3 CU ANSCHUTZ ACCELERATES 17 NEXT GENERATION DEVICE ENABLES COVID-19 RESEARCH 30 DAYS OF CONTINUOUS VITAL SIGNS MONITORING 7 INNOVATORS TAKE ON COVID-19 19 CU ANSCHUTZ CONDUCTS RESEARCH ON 9 UNIVERSITY OF COLORADO A GLOBAL BOSE SLEEPBUDS LEADER IN PATENTS FOR INVENTIONS, INNOVATIONS 21 ECONSULTS COMING 10 CU INNOVATIONS YEAR OF IMPACT TO A PROVIDER NEAR YOU 23 REGENERON & CCPM 13 AWARD PROVIDES FUNDS TO ENERGIZE 25 SUMMIT BIOLABS SPARK INNOVATIONS 27 BIOTECH STARTUPS RAISE MILLIONS 14 SPARK|REACH 2020 FELLO\\WS IN FUNDING 15 GATES CENTER COMMERCIAL EFFORTS 29 THIS IS BREAKTHROUGH FUEL STARTUPS CU Innovations brings together industry partners, entrepreneurs, and investors to help CU researchers solve important problems and improve quality of life worldwide. With expertise in patents, copyrights, and licensing, we help translate discovery into impact through transparent, flexible, best-practice intellectual property management services. We connect researchers at CU Anschutz Medical Campus with a variety of commercialization programs in the university and the community. Partner with CU Innovations: 303-724-4003 | [email protected] www.cuanschutz.edu/cu-innovations 2020 Annual Report 2

CU ANSCHUTZ ACCELER COVID-19 RESEARCH GLOBAL PANDEMIC IMPACTS COLORADO 3 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

R AT E S arly in March 2020, the Building a homegrown network of global COVID-19 pandemic PPE makers reached Colorado when The COVID-19 pandemic represents the first cases were significant risks to the clinicians, nurses, medical assistants, caregivers Econfirmed in the state. and others on the frontlines making In following weeks, the number of a difference in people’s lives. confirmed cases continued to climb Clinicians are desperately seeking as a statewide mandate ordered assistance with hospital personal all non-essential business to close. protective equipment (PPE) in light CU Anschutz responded quickly of predicted shortfalls. Inworks, to ensure the safety of the campus an innovation initiative on both community by transitioning learning, the University of Colorado Denver events and work from in person to and Anschutz Medical Campuses virtual. All attention was now focused (inworks.ucdenver.edu), immediately on finding cures and solutions to began laying the framework for a the multitude of healthcare needs makers’ response organization that required to combat the virus. would seek to include members far The unrelenting work of faculty, beyond their own. Most importantly, researchers, portfolio companies, Inworks held strong to their core and support staff created valuable human-centered design values, resources for testing, PPE creation, going into production for PPE directly research funding, and mental health. in collaboration with Anschutz Medical Campus clinicians. From Addressing mental health during these efforts came the creation of the new normal Make4Covid, a Colorado-based During the past several months, virtual-collaborative community of Matt Vogl and the team at the makers, designers, industry experts, National Mental Health Innovation scientists, academics, and healthcare Center (NMHIC) have been working professionals working together closely with the Department of to design, test and manufacture Psychiatry to implement new medical and PPE for doctors, nurses, technologies for mental health. This and first responders. By June 2020, included deploying virtual reality Make4Covid has been in operation headsets for meditation for staff and for 15 weeks and has created about patients. In addition, NMHIC has 82,000 pieces of PPE. been collaborating with residents and psychiatrists on staff to pilot Pioneering COVID-19 Immune a new virtual reality program for Therapeutics the treatment of phobias. With COVID-19 triggers a massive the increased need for COVID-19 immune response in the lung, with resources, NMHIC has focused consequent recruitment of immune on interviewing providers in the cells and release of inflammatory Department of Psychiatry and the UC cytokines. The ‘cytokine storm’ Health Outpatient Psychiatry Clinic caused by COVID19 is associated on the Anschutz Medical Campus. with acute respiratory distress The interviews focused on the syndrome (ARDS), myocardial importance of self-care and support damage, and multiple organ failure. tools for students during COVID-19. Inhibiting the cytokine storm is now Ultimately, NMHIC’s interviews with being tested in clinical trials in China providers and staff about COVID-19 and soon in the USA to slow down related mental health topics resulted pathology and decrease morbidity in efforts to build resources to cope and mortality during advanced during this difficult time. Episodes COVID19 infection. A project led by exploring how technology can help Joaquin Espinosa, PhD is testing the support medical providers can be use of JAK inhibitors to attenuate the found on crazedpodcast.com. 2020 Annual Report 4

5 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

cytokine storm caused by COVID-19 that this will continue even as we Ventilator innovation to meet to decrease the morbidity and resume a new normal.” unprecedented demand mortality in advanced stages of the Across the globe, healthcare systems infection. Partner companies take on are facing mass shortages in life- COVID-19 saving ventilators. CU Anschutz Serology testing Through the year CU Innovations researchers have developed A team of researchers from CU has invested in companies though innovative solutions that have the Anschutz, including UCHealth and the CU Healthcare Venture Fund potential to bolster the supply of Children’s Hospital Colorado, set and Chancellor’s Discovery and needed resources in the fight against forth to address the shortages in Innovation Fund. These companies COVID-19. available testing by creating an are working to develop the next antibody test for COVID-19. These generation of healthcare technology Thomas Greany, DDS, CU Anschutz serology tests will use raw materials and have received national School of Dental Medicine developed onsite to ensure a recognition for their immediate Faculty, designed a state-of-the- consistent supply of high quality efforts to address the pandemic art backup ventilator system that ingredients. through their healthcare innovations. supports up to 12 patients. Driven to support the current shortage in The antibody test was rolled out BioIntellisense developed a ventilator supply, Dr. Greany used in early June and is considered continuous health monitoring and his background in engineering among the best of the best. The clinical intelligence platform that to design and manufacture a tests are aimed to support UCHealth enables medical-grade monitoring ventilator with parts easily sourced facilities but are also open to sample and management of patients at from local hardware stores. Dr. submissions from outside entities. home for scalable remote care. Greany’s team was contracted “The key piece to these tests is Their technology was deployed to to RK Mission Critical to build six specificity,” said Brian Harry, MD, monitor healthcare workers in the emergency backup ventilators, a PhD, School of Medicine assistant field to detect early symptoms of connection made possible by Steve professor of pathology and medical director of clinical chemistry at “The pandemic has had a profound UCHealth University of Colorado impact on global health. But it has Hospital. “Specificity is a measure of also sparked a global collaboration how often false-positive test results of scientists and researchers unlike occur. If we see reactivity on high anything we’ve seen before.” specificity tests, it is likely that patient actually has antibodies to COVID-19.” “Many of the commercial antibody Don Elliman, Chancellor of CU Anschutz tests in the field have a specificity in the low 90s that is based on COVID-19. The use of the Biosticker VanNurden, MBA, CU Anschutz small testing sets, resulting in a allowed doctors to monitor patients Associate Vice Chancellor and CEO positive predictive value of only remotely, which reduced hospital of the Fitzsimmons Redevelopment 50%,” according to Ashley Frazer- overcrowding and promoted social Authority. UCHealth was a recipient Abel, PhD, assistant professor of distancing. of one of these systems for use rheumatology in the School of during emergency situations Medicine. The CU Anschutz serology Summit Biolabs was founded for requiring additional ventilators. test has a 99.6% specificity, which early detection of head and neck The future of this project involves was determined by testing more than cancer through saliva testing. The acquiring FDA approval to allow 1,000 pre-pandemic samples and faculty formed a startup and are distribution of this ventilator system finding only four false-positives. currently working to adopt their novel through health systems across the technology to COVID-19 testing by nation. “For many of us involved, this diagnosing the existence of virus has been particularly fulfilling through saliva testing. This would As the pandemic continues, CU and engaging,” Harry said of the help overcome major challenges Anschutz remains committed collaboration. “It’s hard to think about around controlling the pandemic to supporting researchers and it that way, because there are people by enabling an easy and low cost partnerships to advance the dying of COVID-19, but the pandemic solution to testing. development of innovations to fight has brought our community together the spread of COVID-19. in ways that it hadn’t before. I hope 2020 Annual Report 6

INNOVATORS Brian L Harry, MD, PhD TAKE ON COVID-19 SOM, Department of Pathology Organized task-force to implement serology testing for the state of Colorado Charles Neff, Ph.D. Christene A. Huang, Ph.D. SOM, Allergy, Asthma and Clinical Immunology SOM, Department of Surgery Developing an innovative Researching plasma galetin-3 diagnostic tool to detect to determine COVID-19 COVID-19 infection and developing antibodies to prevent and treat Cristos Ifantides, MD severe infection SOM, Department of Diego Restrpo, Ph.D. Ophthalmology SOM, Department of Created a multi-use and readily Neurology adaptable 3D-printed modular mask system. Identifying pathways that can be targeted by repurposed drugs to treat COVID- 19 James P. Maloney, MD Joaquin Espinosa, PhD SOM, Department of SOM, Linda Crnic Institute for Pulmonary Sciences and Down Syndrome - Department Critical Care Medicine of Pharmacology Treating COVID-19 by inhibiting Developing non-vaccine TGF-Beta based COVID-19 immune therapeutics 7 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

Kambez Benam, PhD Kenneth W. Liechty, MD SOM, Departments of Medicine SOM, Department of Surgery and Bioengineering Developing a treatment for Developing an inhalable COVID-19 induced adult COVID-19 treatment respiratory distress syndrome Maria A Nagel, M.D Mario L. Santiago, PhD SOM, Department of SOM, ID Division Neurology Researching the effects of Identifying pathways that can interferons for COVID-19 be targeted by repurposed drugs to treat COVID- 19 Phil Reigan, PhD V. Michael Holers, MD SOM, Department of Pharmaceutical Sciences SOM, Department of Developing a non-vaccine Rheumatology based therapeutic to treat Organized task-force to COVID-19 implement serology testing for the state of Colorado Thomas Greany, DDS Richard Weir, PhD SOD, Restorative Dentistry Created a multi-patient SOM, Department of BIOE ventilator using parts easily Created a multi-use and readily found in hardware stores adaptable 3D-printed modular mask system Andrew N Bubak, Ph.D. Zhirui Wang, PhD SOM, Department of Neurology SOM, Department of Surgery Identifying pathways that can Researching plasma galetin-3 be targeted by repurposed to determine COVID-19 drugs to treat COVID- 19 infection and developing antibodies to prevent and treat 2020 Annual Report 8 severe infection

UNIVERSITY OF COLORADO A GLOBAL LEADER IN PATENTS FOR INVENTIONS, INNOVATIONS CU LEAPS INTO TOP 20 UNIVERSITIES FOR CONNECTING RESEARCH AND INDUSTRY The University of Colorado “While patents are a critical part of therapeutics and medical devices. jumped from No. 53 to commercialization, our strategy also That creative collaboration had led No. 20 in a recent global heavily emphasizes entrepreneurial to an increase in patent applications, ranking of the top 100 training, mentorship and startup and growing recognition of our universities granted resources,” said Brynmor Rees, campus as a dynamic hub for U.S. utility patents for an array of assistant vice chancellor for commercial innovations that are inventions and innovations that Research & Innovation at CU Boulder transforming health care and saving can have far-reaching and positive and managing director of Venture lives.” impacts on society. Partners at CU Boulder. “This jump in our ranking shows that our engine The report uses data obtained from The National Academy of Inventors of new innovations powers our the U.S. Patent and Trademark Office (USPTO) and highlights the vital role “At CU Anschutz, our CU Innovations team embodies our patents play in university research collaborative spirit by connecting industry partners with and innovation. our physicians and researchers...\" Published annually since 2013, the Don Elliman, report ranks the top 100 universities Chancellor of CU Anschutz named as first assignee on utility patents granted by the USPTO in the (NAI) and the Intellectual Property holistic approach of bringing ideas to 2019 calendar year. Owners Association (IPO) announced market.” recently the 2019 rankings. All four “The institutions included in campuses contributed to CU’s total “The University of Colorado’s focus this year’s report are leading 92 patents. on innovation is yielding impressive innovation worldwide through results, and we continue to see their encouragement of academic “This is yet another demonstration of forward momentum,” said Donald discovery and invention,” said Paul R. the innovative, entrepreneurial spirit M. Elliman Jr., Chancellor of the Sanberg, NAI president. of faculty across the CU system,” said University of Colorado Anschutz CU President Mark Kennedy. “Our Medical Campus. “At CU Anschutz, This year’s report on 2019 patents, faculty improve lives, save lives and our CU Innovations team embodies published May 18, lists the total make our state and world a better our collaborative spirit by connecting number of patents for 2019’s Top place. I’m pleased and proud that industry partners with our physicians 100 universities (including U.S. and CU faculty are so adept at securing and researchers in partnerships that international universities) to be 7,873, patents that turn their ideas and lead to diverse projects spanning an increase of 1,046 patents over the research into practical applications biomedical technology, novel previous year. that advance a variety of fields.” 9 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

CU Innovations Year of Impact 2019 - 2020 $170M Funding raised by CU startups $50M Funding raised for venture fund 1700+ Individuals engaged in outreach and education 50+ Industry deals Highest-impact patents from 2019 and their associated CU Anschutz spinoffs: Kahook Dual Blade - US 10,327,947 “Modified Dual-Blade Cutting System,” was created by Malik Kahook, M.D., CU School of Medicine professor in ophthalmology at the CU Anschutz Medical Campus. The Kahook Dual Blade, launched in 2015 by New World Medical, is a novel surgical blade created to produce a more complete removal of trabecular meshwork, which is the eye tissue associated with the development of glaucoma. Glaucoma is a leading cause of irreversible blindness around the globe. Surgery with the Kahook Dual Blade is minimally invasive and can be effectively performed with equal efficacy in modern operating rooms as well as in low-resource areas around the world. It is now one of the most commonly performed glaucoma procedures and backed by extensive evidence- based medicine. Q32 Bio — US 10,233,235 “Modulating the Alternative Complement Pathway” pertains to methods and compositions for modulating, e.g., stimulating or inhibiting, activity of the alternative complement pathway. This therapeutic approach is important because it provides targeted regulation of complement directly in diseased tissues while minimizing the risk of serious infections and other complications associated with systemic complement pathway modulation. The patent is licensed to Q32 Bio, a biotechnology company developing treatments for patients with severe autoimmune and inflammatory diseases. Q32 Bio was seeded and incubated by Atlas Venture with foundational science from renowned researchers in immunology Michael Holers, M.D., and Joshua Thurman, M.D., from the CU School of Medicine at the CU Anschutz Medical Campus. The company raised $46 million in Series A funding and expects to enter into a Phase I trial in 2021. 2020 Annual Report 10

CU Healthcare Innovation F First CU Ventur Fund Raises $5 Historic Fund Aims to Stimulate a New 11 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

The fund will focus on investing in early-stage healthcare companies that have a business relationship with partner institutions Fund The CU Healthcare the University of Colorado Anschutz Innovation Fund Medical Campus. “With the maturing re announced, in June 2020, of our campus innovation ecosystem 50M that it secured its maximum led by CU Innovations, our success targeted committed capital with several early-stage ventures, w Era of $50 million. The fund is affiliated and the proven collaboration with and located at the University of between all of the CU Anschutz Colorado Anschutz Medical Campus. Medical Campus institutions, it was clear the time was right to scale a The limited partners include, among formal stand-alone fund.” others, the University of Colorado, UCHealth, Children’s Hospital While independent of the CU Colorado and CU Medicine, all Anschutz Medical Campus and located at the CU Anschutz Medical its world-class hospital partners, Campus. the fund will utilize its campus relationships to de-risk early-stage The fund will focus on investing in investments in new technologies early-stage healthcare companies that enable clinicians to improve that have a business relationship patient care and better utilize the with the partner institutions. The fund vast amount of healthcare data expects a majority of its investments being generated to improve decision to be focused on digital health and making at the point of care or identify healthcare IT ventures that have a new treatments. The goal is to build co-development relationship with a portfolio of companies that have the campus. The fund will also invest an initial product that can leverage in therapeutics and medical devices the resources of the campus to that have been developed on the evolve that product to better meet campus and licensed to outside the needs of healthcare systems and proven entrepreneurial teams with providers nationally, while improving substantial backing. the patient experience and lowering the cost of care. The fund has already invested in eight companies and continues to pursue new opportunities aggressively. More information on the fund, the portfolio, and the investing team can be found at www. cuvcfund.com. “We have been exploring starting For inquiries contact: a fund of this kind for many years,” [email protected] said Donald Elliman, Jr., Chancellor of 2020 Annual Report 12

AWARD PROVIDES FUNDS TO ENERGIZE SPARK INNOVATIONS NIH REACH Program awards $4 million to CU Anschutz The University of Colorado Through CU Innovations, the office In its second year, part of the funding Anschutz Medical Campus that leads business development for the SPARK program came from has been awarded $4 and commercialization efforts of the Advanced Industries Accelerator million over the next four the CU Anschutz Medical Campus, (AIA) program of the State of years from the National and the SPARK Colorado program, Colorado, Office of Economic Institutes of Health (NIH) Research a commercialization initiative of the Development (OEDIT). AIA was Evaluation and Commercialization office supported by the Chancellor created by the State Legislature in Hubs (REACH) grant. As a result, the Donald Elliman Jr., the campus has in 2006 to support development of University is now part of a national place the expertise and track record biomedical technologies arising from network of research institutions of success in supporting faculty- Colorado’s research institutions. CU sharing best practices around led innovations and accelerating Anschutz will leverage state funds commercialization of academic commercialization. SPARK to attract additional funding from the discoveries. Colorado, founded in 2018, has NIH, industry and investors. been assisting CU Anschutz faculty As the primary funding agency and researchers in the process of The REACH aaward will be a major for biomedical research, the NIH transitioning their discoveries into boost to diversifying Colorado’s has been reflecting on ways to products that will improve health. economy and will bring in major support the translation of early- The program provides funding, actors under a broad umbrella. stage discoveries from the lab to the industry mentorship, and a curriculum University of Colorado Cancer patients. The REACH program has tailored to the needs of participating Center, Colorado Bioscience been a major initiative of the NIH for members. Current projects span Association (CBSA), University of this goal by creating a network of biomedicine ranging from surgery, Colorado Denver Business School, institutions across the country. Most ophthalmology to oncology. The aims the State of Colorado Office of recently, as the second cycle of the of the REACH and SPARK programs Economic Development (OEDIT), REACH program, the NIH awarded are complementary, namely Rockies Venture Club, and the $20 million to fund five medtech providing faculty and researchers Small Business Administration all hubs to speed the translation of early on with necessary skillsets expressed their trust in CU Anschutz biomedical developments into and resources regarding product in building this hub through their commercially viable products. CU development, project management support letters. Anschutz is one of those hubs. and commercialization. Donald Elliman Jr., Chancellor of Richard Duke, PhD, the principal The grant enables CU Anschutz to CU Anschutz, thanked all parties investigator on the Colorado REACH expand and enhance the already within the campus who worked hub grant and a faculty member in successfully established SPARK together and community partners the CU School of Medicine Division program and will be used to who expressed their support for of Medical Oncology stated, “Having support translational projects and realizing CU Anschutz’s full potential been a biomedical researcher their product development efforts. in commercialization. “We are and academic entrepreneur at CU Additional funding will be utilized for honored to be recognized by NIH as Anschutz for nearly 40 years, I am educational initiatives and leveraging a high-impact research institution.\" excited to witness the translation of existing educational resources like Added Chancellor Elliman, \"REACH the numerous and varied inventions the Innovation Corps (I-Corps™) will increase our engagement with of my faculty colleagues into program of the Colorado Clinical technology development experts products that impact patients’ lives, & Translational Sciences Institute and investors,-- toward our end goal which the REACH grant funding will (CCTSI). of developing innovative health support.” products to help patients thrive.” 13 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

SPARK IS NOW POWERED BY NIH REACH 2020 FELLOWS NAT I O NAL I NST I T UT E S O F H EALT H COLORADO Cem Altunbas, PhD Kimberly Bruce, PhD Tom Flaig, MD Associate Professor Assistant Professor Professor Project: An ultra-compact CT Project: LPL activators as novel Project: Multifunctional scanner for point-of-care imaging Nanoclusters for Detection and therapeutics for AD Treatment of Bladder Cancer Jay Hesselberth, PhD Cristos Ifantides, MD MBA Kristine Kuhn, MD PhD Associate Professor Assistant Professor Assistant Professor Project: Methods for Project: iSense: A First-in-Class Project: Novel inhibitors of understanding functional trimethylamine lyase for RA heterogeneity among single cells Therapy for Insufficient Pupil Dilation Zhirui Wang, PhD Maria Nagel, MD PhD Devatha Nair, PhD Associate Professor Assistant Professor Associate Professor Project: Repositioning neurokinin-1 Project: Oral Biofilm Disruption Project: IL2-CCR4 Bispecific receptor (NK-1R) antagonists as and Selective Inhibition of S. Immunotoxin Targeting antiviral agents against human mutans Biofilms Cutaneous T-Cell Lymphoma herpesviruses Learn more about SPARK|REACH: 14 http://sparkcu.org 2020 Annual Report

Gates Center Commercial Efforts Fuel Startups It tends to be a bit more inside tiny polymers for long- injections in each eye – “that’s 700 complicated than a chocolate- term release. As they looked at needle sticks in a lifetime,” Olson in-the-peanut-butter moment, different membranes, they stopped notes. but every Gates Center-related suddenly on kidney dialysis, which medical startup has that instant relies on a sophisticated external “It’s like putting an air filter in the when a break in mindset led to pump-and-filter system to clean the room instead of spraying in an air promising discovery. bloodstream. cleaner,” he said. For eye surgeon Jeffrey Olson, “We saw reports of kidney patients Even with his third startup, Olson M.D., and what would soon become being inflammatory-deficient,” Olson can’t take the next steps alone, he AmpVision LLC, the “a-ha!” moment said. “For them, it was an unwanted said. came as he was researching side effect.” The dialysis process treatment for an entirely different part filtered out “good” inflammatories. “The toughest thing we run into of the body – kidneys. Olson and “For us, there’s too much protein in every time is the ‘valley of death’ – other eye specialists spend a large the eye, and it causes inflammation. you’ve got a great idea, you pitch it, amount of their time dealing with So, why not use the side effect as the they love it, and they say, ‘If you can macular degeneration and diabetic treatment?” raise $500,000 or $1 million to get it retinopathy, affecting more than 10 into patients, we’ll fund the $4 million million people in the U.S. alone. The result of the epiphany is a clinical trial,’ “ Olson said. Neither manufactured device the diameter Olson, an associate professor of Both conditions produce too much of a pencil eraser that is meant to ophthalmology at the School of protein inside the eye. Olson’s be implanted in the eye and filter Medicine who practices at UCHealth team had been studying the out excess proteins over time. The and the VA, nor his colleagues have possibility of “cell encapsulation,” device is modeled to last for years, that kind of walking-around money. which puts therapeutic materials eliminating monthly needle-stick 15 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

2019 - 2020 Grubstake Fund Awardees Terry Fry, M.D. Ram Nagaraj, Ph.D. Optimized manufacturing Therapeutic peptide for of CD19xCd22 CAR- neuroprotection in acute expressing T cells for the closed-angle glaucoma clinic T. Rajendra Holger Russ, Ph.D. Kumar, Ph.D. Generation of functional, Production of patient-specific thymi for efficacious recombinant cell therapy hypoglycosylated FSH glycoform That’s where the Gates Center, the critical piece to connect bench after funding such as federal Small the CU Innovations, the Grubstake research to making patients better.” Business Innovation Research grants, Awards and the Gates Startup Olson said. Toolbox enter the picture for the Olson received help from the Gates 114 Gates-member researchers Grubstake Fund, which provides Through Grubstake and the Startup hoping to take their technology three or four annual awards up to Toolbox, Callahan said, the variety of toward patient treatment. Most $350,000 to support the translational assistance available for researchers researchers – many of whom are development of regenerative is unparalleled. “We connect them also busy clinical providers – need medicine projects into patented, to law firms, lawyers who are used seed money, legal and regulatory clinic-ready products. AmpVision to working with inventors who help expertise, and business advice to has employed some of that funding them form a company and license move their ideas along. for a regulatory consultant to the technology; we help them navigate FDA procedures, and to assemble a management team; “The focus of doing research is for investigate how to start up clinical- we help them obtain non-dilutive the betterment of humanity,” said grade manufacturing if the device is funding…those are the things that Heather Callahan, Ph.D., J.D., EMBA, approved for human trials. make a difference in the success of a who is Entrepreneur in Residence company.” at the Gates Center and CU The presentations and persuasion Innovations. “If you just research it that come with fundraising are “not For application assistance and never translate it into a product my favorite part,” Olson said. “Gates and questions contact: and get it on the market, it doesn’t Grubstake has really gotten us Heather Callahan have all the value it could have. It’s through some of that.” The Gates just the way our society has set this funds are less restricted, for example, [email protected] up. The commercial component is and therefore easier to direct where needed, than other sought- 2020 Annual Report 16

NEXT GENERATION DEVICE ENABLES 30 DAYS OF CONTINUOUS VITAL SIGNS MONITORING CU INNOVATIONS, IN PARTNERSHIP WITH CARE INNOVATION CENTER, SELECTS BIOINTELLISENSE'S BIOSTICKER™ AS A CUTTING-EDGE REMOTE PATIENT MONITORING COMPANY 17 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

ioIntelliSense, Inc., demonstrate the value and clinical a continuous health applications of the BioSticker device monitoring and clinical and medical-grade services. This intelligence company, alliance is committed to developing and validating new models of data- Bannounced on January 28, driven care that are patient-centered 2020 the U.S. commercial launch of and built for scale. its medical grade Data-as-a-Service (DaaS) platform and FDA 510(k) \"The future of healthcare will see clearance of the BioSticker™ on-body the lines blurred between the sensor for scalable remote care. hospital, clinic and home,\" said BioIntelliSense offers a new standard Richard Zane, MD, UCHealth for Remote Patient Monitoring (RPM) Chief Innovation Officer and Chair by combining an effortless patient of Emergency Medicine at the experience with medical grade University of Colorado School clinical accuracy and cost-effective of Medicine. \"The use of the data services. BioSticker device for continuous health monitoring enables us to \"We are at the inception of a monitor a patient in their home and remarkable new era in healthcare recognize when a patient may have that will employ medical grade an exacerbation of illness even sensor technologies to effortlessly before they manifest symptoms. capture remote patient data and This may reduce hospitalizations, generate personalized clinical emergency department visits and intelligence,\" said James Mault, MD, shorten hospital stays, creating cost FACS, CEO of BioIntelliSense. efficiencies for health systems.\" The BioSticker is an advanced on- \"We are proud and excited to be body sensor that allows for effortless working with the innovative teams continuous monitoring of vital signs at UCHealth and the University of and actionable insights, delivered to Colorado Anschutz Medical Campus,\" clinicians from patients in the home Mault said. \"It is a remarkable setting, thereby creating unique collaboration and clinical proving opportunities for early detection of ground for our continuous monitoring potentially avoidable complications. and predictive data services platform. Through the platform's data sets and UCHealth has made it possible for analytics, highly-efficient care is now BioIntelliSense to rapidly accelerate possible at a fraction of the cost of the development of our technology, traditional remote patient monitoring. as well as optimize its clinical validation.\" BioIntelliSense is built on the foundation of a sophisticated team About BioIntelliSense of engineers and data scientists with decades of expertise in BioIntelliSense is ushering in a new wearable sensor development. era of continuous health monitoring With these distinctive capabilities and clinical intelligence for Remote and proprietary technologies, the Patient Monitoring (RPM). Its medical- company is poised to help transform grade Data-as-a-Service (DaaS) platform care delivery under the leadership seamlessly captures minute-to-minute of Dr. Mault, an industry veteran who vital signs, physiological biometrics has an accomplished business and and symptomatic events through an clinical career that has culminated in effortless patient experience. The a number of successful connected FDA-cleared BioSticker™ device makes health ventures. remote monitoring and early detection simple. Through the platform's advanced BioIntelliSense has established a analytics, clinicians will now have access strategic collaboration with UCHealth to high-resolution patient trending and and its CARE Innovation Center to reporting to enable medical grade care in the home. 2020 Annual Report 18

CU ANSCHUTZ CONDUCTS RESEARCH ON BOSE SLEEPBUDS BETTER NOISE MASKING, NEW RELAXATION CONTENT 19 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

arly in September tracks, they help quiet your mind, Line, Boardwalk, and beyond; 10 2020, Bose announced too.\" Tranquilities help lower stress and Sleepbuds™ II, the tension with tones to Lift, Drift, next generation of its The User Tested Study Dream, and more. Erevolutionary bedtime In a first-of-its-kind study, Bose Better — from Noise Masking wearable with technology now partnered with the University of to Bud, Bluetooth to Battery, clinically proven to help people fall Colorado Anschutz Medical Campus Transducer to Tip asleep faster. Sleepbuds II feature and the UCHealth CARE Innovation demonstrably better noise masking Center to test the impact of Bose Bose Sleepbuds II feature than their predecessor and introduce sleep technology — which was advancements in noise management, new categories of content to combat clinically proven to help people fall acoustics, psychoacoustics, and the other barrier to rest: the inability asleep faster. The research also electronic miniaturization. Each bud to relax. They combine a new found that 100% of participants is a just a quarter-inch deep — about acoustic and electronics design, a confirmed Bose noise masking the same as a pencil's eraser — to new enclosure that's lighter than a worked against the common dramatically reduce irritating contact dime, new proprietary ear tips for disturbances that kept them up when your head is resting on a a secure, super-soft fit, and over or woke them up; 86% said the pillow, even on your side. A new 35 free tracks — all methodically product helped them fall asleep anti-friction coating covers each produced and tested. The result is easier; 76% said it helped them stay enclosure to prevent \"squeaking\" an engineering breakthrough: two asleep; and 80% reported an overall against fabric, and a new etched tiny, ultra-comfortable, truly wireless improvement in sleep quality. antenna produces a more reliable buds that block, cover, and replace phone and tablet connection using the audible distractions from loud partners, neighbors, dogs, and traffic — and reduce the mental distractions from long, busy days. Bose Sleepbuds II will be available on October 6th for $249.95. They aren't active noise cancelling headphones or in-ear headphones with an added feature, and they don't stream music or let you take and make calls — because every last detail was optimized for one thing — better sleep, all night, every night. \"Bose Sleepbuds II use New Library of Content — Quiets low-energy Bluetooth. Inside, a new advancements in our proprietary the Room, Quiets the Mind NiMH (Nickel-metal Hydride) battery noise masking technology because powers 10 hours of run time, and a covering sound — not cancelling For control and updates, the free new miniscule circuit board stores it — is a better solution for sleeping,\" Bose Sleep App lets you set an up to 10 files from the Sleep App's said Steve Romine, head of the Bose alarm, change volume, and now library. Its noise-masking tracks are Health Division. \"You can't duplicate includes three categories of matched to a new transducer to the experience combining earbuds content — all precisely developed, \"cover and replace\" more unwanted with apps, playing your music louder, engineered, and mixed to overcome sounds than ever before — while a or using earplugs and bedside what keeps you up or wakes you new pressure equalization design machines — so millions of people are up. When that's caused by noise, and soft silicone tips \"block\" more still suffering. We never gave up on 14 noise-masking tracks mirror the from entering your ear. With three helping them, and that's why we're frequencies of night-time disruptions, sizes included, the tips are different so excited about Sleepbuds II. They hiding them under soothing layers than those made for daytime use. 'quiet' more of the low frequencies of audio. When it's caused by how Their materials, shape, and design found in the biggest threats to a you feel, new relaxation options are all optimized to stay in place for a peaceful bedroom — like snoring are now available: 15 Naturescapes full night of peaceful, pain-free rest. partners, idling engines, and nearby help calm racing thoughts with footsteps. And with new relaxation walks down a Country Road, Shore 2020 Annual Report 20

EC O N S ULTS C OMI NG TO A PROVIDER NEAR YOU UNIVERSITY OF COLORADO SCHOOL OF MEDICINE AND ARISTAMD PARTNER TO EXPAND ECONSULTS TO COMMUNITY PROVIDERS 21 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

ristaMD, an innovative patients to receive timely, effective telehealth platform treatment. that delivers primary care providers (PCPs) “After conducting an extensive competitive evaluation, we selected Atimely and documented AristaMD for their best-in-class technology, service and ability to specialist insight through eConsults, launch the eConsult platform directly has partnered with the University of through the Epic EHR, creating Colorado School of Medicine (CU) a user-friendly experience for to expand eConsults to a network answering eConsults with minimal of community providers. The provider burden and workflow partnership begins with Salud Family changes,” said Anne Fuhlbrigge, MD, Health Center, which has 13 clinic Senior Associate Dean for Clinical locations and serves communities in Affairs at the University of Colorado. northeast and southeast Colorado. \"Access to specialty care knowledge is a critical issue for our providers as well as our patients,” Tillman Farley, MD, Chief Medical Officer at Salud Family Health Centers “AristaMD is pleased to be working According to data from primary care with our first partner that is a part physicians who use the AristaMD of the Association of American platform, eConsults reduce the need Medical Colleges’ Project CORE: for face-to-face specialist visits in Coordinating Optimal Referral over 70% of cases, improving access Experiences. We can support and reducing incurred costs related health systems, including those to travel and time away from work already using eConsults within – all while preserving the quality of their own electronic health records care. Patients can avoid the out-of- (EHR), to more broadly expand to pocket expense of a specialty visit clinics on any system,” said Brooke by relying on an eConsult, saving a LeVasseur, CEO of AristaMD. “The significant amount, according to data AristaMD platform works with all from CU. EHRs, seamlessly integrates into physician workflows, and will allow “Access to specialty care knowledge us to scale to community providers is a critical issue for our providers throughout the state of Colorado as as well as our patients,” said Tillman the partnership grows.” Farley, MD, Chief Medical Officer at Salud Family Health Centers. “By AristaMD will empower primary partnering with CU and AristaMD, care providers with the ability to our providers will be able to consult conduct eConsults with specialists specialists on patient questions that from the University of Colorado don’t require the patient to see a School of Medicine, who will provide specialist in-person. This eConsult recommended treatment pathways system allows specialists and primary for specific patient cases. Providers care providers to work together to already using AristaMD’s telehealth ensure the best care for patients. platform report that eConsults It allows us to improve access to significantly impact the care plan care while decreasing costs. That in over 90% of patient cases, improves patient outcomes and expanding the scope of care for the satisfaction with care for patients and primary care provider and allowing providers.” 2020 Annual Report 22

REGENERON & CCPM PARTNERS IN GROUND BREAKING HUMAN GENETICS RESEARCH 23 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

egeneron Pharmaceuticals, breadth of its capabilities, allowing improved medicines, as well as Inc. (NASDAQ: REGN) and us to give more back to our patient the advancement of validated and the Colorado Center for participants than ever before,” said improved risk scores in medicine, Personalized Medicine Kathleen Barnes, Ph.D., Professor both scale and quality of data matter. and Director of CCPM at the This partnership opens up new R(CCPM) at the University University of Colorado Anschutz doors for meaningful discovery, of Colorado Anschutz Medical Medical Campus. “We have made strengthens Regeneron’s ability Campus announced a large-scale tremendous strides with our work to speed and improve the drug research collaboration designed to in pharmacogenomics, but having development process, and allows advance the field of human genetics access to such a large genomic us to work alongside other leaders and precision medicine through the dataset that enables the return of in the advancement of genomic and sharing of 450,000 DNA samples clinically actionable results will be precision medicine.” and corresponding health records transformative. Our collaboration with from de-identified, consented the RGC will lead to an optimization The impressive scope of this effort patient participants in the expansive of patient care, using personalized is also thanks to the wide-ranging UCHealth system. The Regeneron results to better inform clinical footprint of UCHealth. Large numbers Genetics Center (RGC), a wholly decision making, and potentially of the nonprofit health care system’s owned subsidiary of Regeneron, \"This collaboration will take an already notable program at the CCPM and expand the depth and breadth of its capabilities, allowing us to give more back to our patient participants than ever before.\" Kathleen Barnes, Ph.D. Division Head of Biomedical Informatics and Personalized Medicine has entered into the collaboration leading to new ways of diagnosing, patients have consented to biobank with CCPM and will sequence preventing and treating illnesses.” participation, more than half of whom these samples, producing genomic live outside of the metro Denver data that can be used to facilitate One of the world’s largest genetics area and in neighboring states like translational medical research and databases was created pairing Nebraska and Wyoming. ultimately enable physicians to make the sequenced exomes and de- better decisions for their patients. identified electronic health records “Our patients are already benefitting of more than one million people. from the remarkable work of the CCPM is one of the largest health This database is a collaboration CCPM, which is allowing providers data warehouses in the United with more than 80 global healthcare to use genomics to make more States and a pioneer in the use of and academic institutions. Building accurate diagnoses and precisely a secure cloud platform with more upon Regeneron’s strengths in tailor treatment to individual than 8.7 million de-identified patient genetics-driven drug discovery, patients,” said Richard Zane, M.D., records. The five-year old research the information secured from this UCHealth Chief Innovation Officer, enterprise is also one of the first initiative will allow for the elucidation, who is also the Professor and Chair and largest programs in the country on a large scale, of genetic factors of Emergency Medicine at the to integrate personalized genomic that cause or influence a range of University of Colorado School of information with clinical data via a human diseases. Medicine. “This partnership will help research biobank. CCPM physicians drive the health care discoveries will validate any genetic findings from “We’re excited to collaborate of tomorrow and realize the full the RGC data in their CLIA-certified with the CCPM and UCHealth to potential of precision medicine. lab, enabling the return of clinically- further expand the RGC’s large- We so appreciate our patients who actionable results to patients. scale genomics initiatives,” said have consented to participate and Aris Baras, M.D., Senior Vice without whom discovery would not “This collaboration will take an President at Regeneron and be possible.” already notable program at the Head of the Regeneron Genetics CCPM and expand the depth and Center. “In the search for new and 2020 Annual Report 24

SUMMIT BIOLABS DEVELOPS TEST FOR HEAD AND NECK CANCERS 25 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

ead and neck cancer is at CU Anschutz. Dr. Song recognized and now advisor to Summit Biolabs; the common term that the clinical need for monitoring Bob Blomquist, healthcare industry encompasses a complex cancer recurrence to choose the executive and now CEO of Summit spectrum of diseases. best therapies for the patient, and Dr. Biolabs; Brian Harry, MD, PhD, clinical Lu recognized the potential for using pathologist at CU Anschutz and HThe heading includes microRNAs as a genetic biomarker now Chief Laboratory Officer; and cancers that start in the nasal cavity, and saliva as the sample. Together Abby Wright, senior executive in sinuses, lips, mouth, thyroid glands, with their research team, they have reimbursement, and now advisor to salivary glands, pharynx, or larynx, devised a gamut of clinical utilities Summit Biolabs. yet methods for early detection of for HNKlear, ranging from use as any have remained elusive. Fulfilling a diagnostic tool to the ability to While they have received the first this need for improved diagnostic monitor progression and recurrence notice of allowance of HNKlear’s tools has become the mission of in patients. patent, filed with the assistance Summit Biolabs, a University of of Summit Biolabs’s attorney and Colorado Anschutz Medical Campus More than just research and Heather Callahan, Portfolio Manager startup, and its molecular oncologist development has been occupying at CU Innovations, Dr. Lu is not founder, Shi-Long Lu, MD, PhD. Dr. Lu’s time. Summit Biolabs is the resting on his laurels. The list of brainchild of over a year of after-work immediate objectives for HNKlear Summit Biolabs’s first product in and behind-the-scenes planning includes filing for international patent development is called HNKlear, and organization. Despite all of his protection, validating clinical utilities which tests for head and neck scientific expertise, Dr. Lu found beyond monitoring, developing its cancer recurrence following front- himself in a strange, new world, that use as guidance for personalizing line treatment by detecting certain of patents and business startups, in patient therapies, and collaborating modifications to tumor DNA. What working to bring Summit Biolabs to with pharmaceutical companies sets it apart is that HNKlear is a fruition and HNKlear to market. To on development and distribution. liquid biopsy test using samples About Shi-Long Lu, MD, PhD: Dr. Lu received his M.D. degree from China Medical University, and his Ph.D. Degree on Molecular Oncology from Tokyo Medical and Dental University. He completed his post-doctoral training in the Howard Hughes Medical Institute Lab at the Case Western Reserve University. He was an Assistant Professor of Otolaryngology, and Dermatology at the Oregon Health & Science University. He is currently an Assistant Professor of Otolaryngology, Dermatology, and Pathology at the University of Colorado Denver School of Medicine. from an obvious and abundant help him make the leap to scientist Their most ambitious target is to source: saliva. As Dr. Lu noted, entrepreneur, Dr. Lu has relied on make HNKlear available as an early saliva is a natural resource given its both his network and the services screening test in medical, and even ready availability and the anatomic offered by CU Innovations. dental, offices. Dr. Lu once thought location of most head and neck the widespread accessibility of a cancers. The development of Early funding for HNKlear came test like HNKlear for early cancer HNKlear drew on a number of Dr. from the SPARK program, and since screening would be a tremendous Lu’s experiences, marrying his their introduction, Dr. Lu has looked hurdle. These days, he’s heartened postdoc work on a noninvasive test to SPARK and CU Innovations for to see it becoming closer to reality as for colorectal cancer, which evolved “help, training, and advocating for dental offices shift towards providing over time into the Cologuard® scientists and clinicians to become more general practitioner services. test from Exact Sciences, with his scientist entrepreneurs and know chosen specialization in head and what the business world looks Looking even further ahead, Dr. neck squamous cell carcinoma. His like.” Specifically, he participated Lu has clear ambitions for Summit familiarity with both laboratory and in the SPARK program for step- Biolabs. Expansion plans include the clinical research has pushed Summit by-step trainings in intellectual development of tests based not just Biolabs to thoroughly explore the property rights, market research, on saliva but also on other bodily potential of HNKlear. business team formations, and fluids, such as sputum and cervical investments. What Dr. Lu has found discharge, and the detection of not To bring the clinic and the laboratory most beneficial of all has been the just head and neck squamous cell together, Dr. Lu collaborated with Dr. industry and business connections, carcinoma but all types of squamous John Song, a surgical oncologist and in particular: Stan Lapidus, founder of cell carcinomas, such as those in Director of Head and Neck Surgery Exact Sciences, serial entrepreneur, lung, esophagus, or cervical areas. 2020 Annual Report 26

BIOTECH STARTUPS RAISE MILLIONS IN FUNDING Q32 Bio Raises $46M in Series A activity specifically in disease- included Atlas Venture, OrbiMed Funding affected tissues. The company is led Advisors, Abingworth, Sanofi by industry veterans Michael Broxson Ventures, University of Colorado and Q32 Bio, a biotechnology as Chief Executive Officer, and co- Children’s Hospital Colorado Center company developing founder, Shelia Violette, Ph.D., as for Innovation. biologics to restore healthy Chief Scientific Officer and President immune regulation, announced of Research. “Autoimmune and inflammatory the company’s pipeline and plans diseases are driven by dysregulation to enter the clinic this year with Q32 Bio was seeded and incubated of the immune response,” said Mr. its lead candidate. Enabled by a by Atlas Venture with foundational Broxson. “Q32 Bio has a preeminent $46M Series A financing led by science from renowned researchers team with expertise in both innate Atlas Venture, and a world class in immunology Michael Holers, M.D. and adaptive immunity, a board of team and Scientific Advisory Board, and Joshua Thurman, M.D., both directors and scientific advisory Q32 Bio is advancing a portfolio from the University of Colorado, and board made up of leaders in our of biologics targeting the body’s Steven Tomlinson, Ph.D. from the field, and a syndicate of blue-chip innate and adaptive immune Medical University of South Carolina. investors. This gives us a running systems. The company has a Dr. Holers serves as chairman start in developing therapies that robust product pipeline including a of the Scientific Advisory Board, may improve and save lives. I am monoclonal antibody antagonist of which is comprised of distinguished thrilled to join Q32 Bio and look the interleukin-7 receptor (IL-7R), and global experts in autoimmune and forward to advancing our first two a complement therapeutics platform inflammatory disease. immune-regulating therapies into that has generated fusion proteins first-in-human studies planned for that downregulate complement The subsequent Series A financing 2020 and 2021.” 27 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

Ulli Bayer, PhD Neurexis Therapeutics Created to Focus on CU Anschutz School of Medicine Neuroprotective Innovation Department of Pharmacology Neurexis Therapeutics, Inc. was formed in April, 2020 to develop a new medication for the prevention of brain damage following ischemic events such as stroke. Cerebral ischemia is the loss of blood flow to the brain and can be caused by stroke, cardiac arrest, sickle cell anemia, congenital heart defects, high-risk vascular surgery, coronary disease, and other issues. While restoring blood flow to the brain is imperative, the re-establishment of blood flow triggers a cascade of inflammatory events. This results in extensive nerve cell death and significant cognitive and functional impairment. Strokes cost the United States an estimated $34B each year and greatly reduce the quality of life for many patients. Professor Ulli Bayer at the University of Colorado has spent the last decade searching for a solution to this critical healthcare problem. As a result of these efforts, he and his team have developed an optimized drug called tatCN19o, which dramatically reduces both the cognitive and behavioral problems that result from loss of blood flow to the brain. IM Therapeutics Raises $10 Million Financing ImmunoMolecular Therapeutics (“IM Therapeutics”), a clinical stage company developing personalized therapies for autoimmune disease, today announced that it has raised $10 million in Series A financing to advance its novel HLA-targeted discovery platform and develop its lead drug candidate in type 1 diabetes (T1D). The funding was co-led by the JDRF T1D Fund and Morningside Ventures, with participation from the CU Healthcare Innovation Fund. IM Therapeutics was founded by world-class physician Peter Gottlieb, MD Aaron Michels, MD scientists at the Barbara Davis Center for Diabetes, University of Colorado. Their seminal research showed CU Anschutz School of Medicine that blocking action of certain human leukocyte antigen Barbara Davis Center for Diabetes (HLA) gene variants known to be high risk factors blocks the corresponding autoimmune response. “Our value has been clear since day one – getting to the root cause of autoimmunity with a targeted therapy approach and making an impact on diseases such as type 1 diabetes,” said Nandan Padukone, Ph.D., CEO of IM Therapeutics. 2020 Annual Report 28

THIS IS BREAKTHROUGH CU Anschutz launches national brand campaign When an academic Telling the world it will be. medical campus attracts the best Early in January 2020, CU Anschutz “With this marketing effort, we aim minds in science and launched a new identity and to make the University of Colorado unleashes them on advertising campaign, This is Anschutz Medical Campus name the biggest challenges in health care, Breakthrough, that showcases how renowned from coast to coast, and barriers simply don’t stand a chance. the three entities on campus – the our brand synonymous with world- University of Colorado, Children’s class health science and care,” he When a campus combines world- Hospital Colorado and UCHealth said. class clinical practice, education and University of Colorado Hospital – research, diseases and complex deliver cutting-edge health science Partnerships fuel breakthroughs problems run for cover. and patient care. Elliman notes that a main contributor When dynamic collaboration is in CU Anschutz Chancellor Don Elliman to our success is the fact that we our DNA – finding new ways to work often makes the point that, for more share a campus with two outstanding together to improve and transform than a decade, our campus has hospital partners, delivering top- lives – anything is possible. been constructing new buildings and quality care from pediatrics to recruiting top talent to address the geriatrics. Those of us who work here already world’s most pressing health issues. know that, every day, the CU With an unwavering commitment to “This new campaign distills the Anschutz Medical Campus pushes discovery and transformational health essence of this place: how, the boundaries in innovation, care care, our momentum is undeniable. together with our hospital partners, and discovery. we’re breaking down barriers in But it’s all happened rather quietly. health science to accomplish the Now, the world will see it as well. It’s a story that needs to be told. Now extraordinary,” he said. This is … BREAKTHROUGH. 29 CU INNOVATIONS | UNIVERSITY OF COLORADO ANSCHUTZ MEDICAL CAMPUS

Learn more about CU Innovations: www.cuanschutz.edu/cu-innovations Contact us: (303) 724 - 3720 [email protected] Follow us: Twitter - @cuinnovations LinkedIn - bit.ly/LinkedInCUI Created by: Rolfe Bautista | CU Innovations 2020 Annual Report 30

303-724-4003 | [email protected]​